Activity of the novel Fabl inhibitor Debio 1452 against intracellular forms of susceptible and resistant S. aureus: comparison with linezolid, vancomycin and daptomycin

Presented at ECCMID 2016, Amsterdam, NL

Frédéric Peyrusson (1), Françoise Van Bambeke (1), Guennaëlle Dieppois (2), Frederick Wittke (2), Paul M. Tulkens (1)

1. Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium
2. Debiopharm International SA, Lausanne, Switzerland